When autocomplete results are available use up and down arrows to review and enter to select. Touch device users, explore by touch or with swipe gestures.
Before it's here, it's on the Bloomberg Terminal.Learn More
Moderna Is Developing Vaccines to Target Covid-19 Variants
Before it's here, it's on the Bloomberg Terminal.Learn More
When autocomplete results are available use up and down arrows to review and enter to select. Touch device users, explore by touch or with swipe gestures.
Key Statistics
P/E Ratio--
PEGY Ratio--
Shares Outstanding400.53M
Price to Book Ratio26.5939
Price to Sales Ratio83.8554
1 Year Return264.59%
30 Day Avg Volume8,683,000
EPS-1.95
Dividend--
Last Dividend Reported--
Earnings Announcement for Period Ending Q1/2021:05/06/2021
Moderna, Inc. operates as a clinical stage biotechnology company. The Company focuses on the discovery and development of messenger RNA therapeutics and vaccines. Moderna develops mRNA medicines for infectious, immuno-oncology, and cardiovascular diseases.Address
200 Technology Square
Cambridge, MA 02139
United States
